Subscribe
shutterstock_723369586_phushutter
Phushutter / Shutterstock.com
20 June 2019Big Pharma

Amphastar enters into $59m settlement with Sandoz and Momenta

US pharmaceutical company Amphastar Pharmaceuticals is to receive $59.9 million in a settlement agreement with two of its competitors, Sandoz and Momenta Pharmaceuticals.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Adamas settles Gocovri clash with Sandoz
3 January 2020   California-based Adamas Pharmaceuticals has entered into a settlement agreement with Novartis’ generics unit Sandoz over a treatment for dyskinesia, the involuntary movements in Parkinson’s disease patients.
Americas
Judge approves $120m Momenta and Sandoz settlement
6 January 2020   A US federal judge has given preliminary approval to the proposed settlement in the class action suit led by Nashville General Hospital against Momenta Pharmaceuticals and Sandoz over their alleged manipulation of drug testing protocols.
Big Pharma
Sanofi-Aventis gets $17.2m in fees from failed Amphastar suit
6 May 2021   Sanofi-Aventis has been awarded $17.2 million in attorney fees, legal expenses and interest in a district court ruling on a failed suit levied by Amphastar Pharmaceuticals.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Americas
Adamas settles Gocovri clash with Sandoz
3 January 2020   California-based Adamas Pharmaceuticals has entered into a settlement agreement with Novartis’ generics unit Sandoz over a treatment for dyskinesia, the involuntary movements in Parkinson’s disease patients.
Americas
Judge approves $120m Momenta and Sandoz settlement
6 January 2020   A US federal judge has given preliminary approval to the proposed settlement in the class action suit led by Nashville General Hospital against Momenta Pharmaceuticals and Sandoz over their alleged manipulation of drug testing protocols.
Big Pharma
Sanofi-Aventis gets $17.2m in fees from failed Amphastar suit
6 May 2021   Sanofi-Aventis has been awarded $17.2 million in attorney fees, legal expenses and interest in a district court ruling on a failed suit levied by Amphastar Pharmaceuticals.

More on this story

Americas
Adamas settles Gocovri clash with Sandoz
3 January 2020   California-based Adamas Pharmaceuticals has entered into a settlement agreement with Novartis’ generics unit Sandoz over a treatment for dyskinesia, the involuntary movements in Parkinson’s disease patients.
Americas
Judge approves $120m Momenta and Sandoz settlement
6 January 2020   A US federal judge has given preliminary approval to the proposed settlement in the class action suit led by Nashville General Hospital against Momenta Pharmaceuticals and Sandoz over their alleged manipulation of drug testing protocols.
Big Pharma
Sanofi-Aventis gets $17.2m in fees from failed Amphastar suit
6 May 2021   Sanofi-Aventis has been awarded $17.2 million in attorney fees, legal expenses and interest in a district court ruling on a failed suit levied by Amphastar Pharmaceuticals.

More features

Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal
UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
Kathi Vidal to rejoin previous firm as partner following USPTO departure
GSK triumphs in EPO appeal, revoking Pfizer patent